VRDN · Viridian Therapeutics, Inc.\de - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $77.63M | - | $86.26M | $86.63M | $76.83M | - | $69.16M | $56.19M | $40.94M | - |
| SG&A | $17.10M | - | $24.32M | $20.22M | $17.10M | - | $14.41M | $16.07M | $15.03M | - |
| Total Operating Expenses | $116.31M | - | $110.58M | $106.84M | $93.94M | - | $83.57M | $72.26M | $55.97M | - |
| D&A | $121.0K | - | - | - | $117.0K | - | - | - | $145.0K | - |
| Operating Income | ($116.17M) | - | ($40.01M) | ($106.77M) | ($93.87M) | - | ($83.48M) | ($72.19M) | ($55.90M) | - |
| Interest Expense | $3.46M | - | $560.0K | $514.0K | $587.0K | - | $600.0K | $166.0K | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($104.90M) | - | ($34.60M) | ($100.73M) | ($86.91M) | - | ($76.69M) | ($64.99M) | ($48.54M) | - |
| EPS - Basic | - | - | - | - | - | - | ($1.15) | ($1.02) | ($0.79) | - |
| EPS - Diluted | - | - | - | - | - | - | ($1.15) | ($1.02) | ($0.79) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $176.35M | $212.38M | $169.65M | $117.32M | $116.22M | $99.59M | $200.32M | $107.67M | $91.64M | $102.83M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $13.31M | $8.68M | $10.06M | $8.52M | $3.89M | $2.14M | $6.34M | $3.14M | $2.68M | $2.24M |
| Current Assets | $784.74M | $894.23M | $571.91M | $578.75M | $657.24M | $738.46M | $767.36M | $581.66M | $626.82M | $486.48M |
| Total Assets | $789.02M | $899.42M | $577.14M | $582.32M | $660.98M | $742.40M | $771.90M | $585.66M | $630.38M | $490.42M |
| Current Liabilities | $51.80M | $70.70M | $50.70M | $52.59M | $33.73M | $47.87M | $41.36M | $36.76M | $26.13M | $26.64M |
| Long-term Debt | - | - | $20.89M | $12.35M | $20.68M | $20.58M | $20.52M | $20.20M | $20.33M | $20.20M |
| Total Liabilities | $153.01M | $177.25M | $74.17M | $67.16M | $56.51M | $70.76M | $64.40M | $56.33M | $47.85M | $48.40M |
| Stockholders' Equity | $636.01M | $722.17M | $502.97M | $515.17M | $604.47M | $671.64M | $707.50M | $529.34M | $582.53M | $442.02M |
| Retained Earnings | ($1.44B) | ($1.34B) | ($1.22B) | ($1.18B) | ($1.08B) | ($995.86M) | ($916.13M) | ($839.44M) | ($774.45M) | ($725.91M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($119.65M) | - | - | - | ($92.65M) | - | - | - | ($45.22M) | - |
| Investing Cash Flow | $77.26M | - | - | - | $100.06M | - | - | - | ($143.04M) | - |
| Financing Cash Flow | $6.36M | - | - | - | $9.21M | - | - | - | $177.08M | - |
| CapEx | $23.0K | - | - | - | $86.0K | - | - | - | $0 | - |
| Free Cash Flow | ($119.68M) | - | - | - | ($92.74M) | - | - | - | ($45.22M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.14 | - | - | - | 1.07 | - | - | - | 0.93 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.3% | - | -6.0% | -17.3% | -13.1% | - | -9.9% | -11.1% | -7.7% | - |
| Return on equity | -16.5% | - | -6.9% | -19.6% | -14.4% | - | -10.8% | -12.3% | -8.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 15.15 | 12.65 | 11.28 | 11.01 | 19.49 | 15.43 | 18.55 | 15.82 | 23.99 | 18.26 |
| Quick ratio | 15.15 | 12.65 | 11.28 | 11.01 | 19.49 | 15.43 | 18.55 | 15.82 | 23.99 | 18.26 |
| Cash ratio | 3.40 | 3.00 | 3.35 | 2.23 | 3.45 | 2.08 | 4.84 | 2.93 | 3.51 | 3.86 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 0.04 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.05 |
| Debt / Assets | - | - | 0.04 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -33.6x | - | -71.5x | -207.7x | -159.9x | - | -139.1x | -434.9x | - | - |
| Equity multiplier | 1.24 | 1.25 | 1.15 | 1.13 | 1.09 | 1.11 | 1.09 | 1.11 | 1.08 | 1.11 |
| Liabilities / Assets | 0.19 | 0.20 | 0.13 | 0.12 | 0.09 | 0.10 | 0.08 | 0.10 | 0.08 | 0.10 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.5x | - | - | - | - | - | 2.1x | 1.6x | 1.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -23.8% | - | 52.1% | -47.9% | -67.9% | - | -63.0% | -21.8% | 22.9% | - |
| Net income growth (YoY) | -20.7% | - | 54.9% | -55.0% | -79.0% | - | -60.9% | -18.0% | 28.8% | - |
| EPS growth (YoY) | - | - | - | - | - | - | -5.5% | 19.7% | 50.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -29.0% | - | - | - | -105.1% | - | - | - | 27.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 5.2% | 7.5% | -28.9% | -2.7% | 3.8% | 51.9% | 149.5% | 67.6% | 66.2% | 11.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Viridian Therapeutics against the 5 most active filers in the same SIC group.